


# IN THE STATES: KANSAS



The economic footprint of the biopharmaceutical industry can be measured by traditional indicators of employment and output, and its impact on the vendors, large and small, that provide services or supplies to America's biopharmaceutical research companies. The data below illustrates jobs, economic impact and clinical trial data for the industry as a whole, and vendor/supplier data from 15 major biopharmaceutical companies regarding their business relationships and total expenditures paid to vendors in **Kansas** in 2022.

## JOBS & ECONOMIC IMPACT<sup>1</sup>



Economic Output:

**\$11.3B**



Direct Jobs Supported by the Industry:

**7,989**



Total Jobs Supported by the Industry:

**34,771**

## VENDOR & SUPPLIER IMPACT<sup>2</sup>



Total Vendor Relationships:

**329**



Total Vendor Spending:

**\$393,259,598**

## CLINICAL TRIAL IMPACT<sup>3</sup>



Total Clinical Trials:

**1,399**



Total Clinical Trial Participants:

**1,377,261**

**Source:**

- [TEconomy Partners, LLC. The Economic Impact of the U.S. Biopharmaceutical Industry: 2022 National and State Estimates. May 2024.](#)
- [WeWorkForHealth.org/in-the-states](#)
- [ClinicalTrials.gov.](#) Search criteria: In Kansas | Phase: Early Phase 1, 1, 2, 3 | Funded by Industry | Study start on or after 01/01/2019 | Search performed 06/30/24